Analysts Expect TherapeuticsMD Inc (NASDAQ:TXMD) Will Post Earnings of -$0.19 Per Share

Equities research analysts predict that TherapeuticsMD Inc (NASDAQ:TXMD) will report earnings of ($0.19) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for TherapeuticsMD’s earnings, with estimates ranging from ($0.21) to ($0.17). TherapeuticsMD reported earnings of ($0.16) per share during the same quarter last year, which would indicate a negative year over year growth rate of 18.8%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that TherapeuticsMD will report full year earnings of ($0.75) per share for the current fiscal year, with EPS estimates ranging from ($0.80) to ($0.68). For the next financial year, analysts forecast that the company will report earnings of ($0.37) per share, with EPS estimates ranging from ($0.63) to $0.05. Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.01). TherapeuticsMD had a negative return on equity of 212.57% and a negative net margin of 913.07%. The company had revenue of $6.08 million during the quarter, compared to the consensus estimate of $5.12 million. During the same quarter in the prior year, the business earned ($0.15) earnings per share. The firm’s revenue for the quarter was up 60.0% on a year-over-year basis.

TXMD has been the topic of several recent research reports. JPMorgan Chase & Co. reduced their price target on TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, June 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research report on Wednesday, August 7th. Noble Financial restated a “buy” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research report on Monday, August 12th. Cowen reduced their price target on TherapeuticsMD from $16.00 to $9.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 11th. Finally, ValuEngine upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $9.28.

Shares of NASDAQ:TXMD traded down $0.11 during midday trading on Friday, hitting $2.86. The company had a trading volume of 3,394,700 shares, compared to its average volume of 3,923,795. TherapeuticsMD has a 12 month low of $1.82 and a 12 month high of $6.94. The company has a current ratio of 5.17, a quick ratio of 3.28 and a debt-to-equity ratio of 24.29. The stock has a market cap of $658.54 million, a price-to-earnings ratio of -4.85 and a beta of 1.90. The firm has a fifty day simple moving average of $2.47 and a 200 day simple moving average of $3.89.

In other news, Director Angus C. Russell purchased 35,000 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were purchased at an average price of $2.83 per share, with a total value of $99,050.00. Following the purchase, the director now directly owns 73,500 shares of the company’s stock, valued at approximately $208,005. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Brian Bernick purchased 10,000 shares of the company’s stock in a transaction on Friday, August 9th. The stock was purchased at an average cost of $2.87 per share, for a total transaction of $28,700.00. Following the purchase, the director now directly owns 62,000 shares in the company, valued at $177,940. The disclosure for this purchase can be found here. Insiders have purchased a total of 115,549 shares of company stock worth $340,267 in the last ninety days. 18.91% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in shares of TherapeuticsMD in the first quarter valued at about $249,000. Amalgamated Bank increased its position in shares of TherapeuticsMD by 145.3% in the fourth quarter. Amalgamated Bank now owns 26,314 shares of the company’s stock valued at $100,000 after acquiring an additional 15,586 shares during the last quarter. Cetera Advisors LLC increased its position in shares of TherapeuticsMD by 13.8% in the first quarter. Cetera Advisors LLC now owns 77,725 shares of the company’s stock valued at $380,000 after acquiring an additional 9,450 shares during the last quarter. Private Ocean LLC acquired a new stake in shares of TherapeuticsMD in the first quarter valued at about $37,000. Finally, FMR LLC increased its position in shares of TherapeuticsMD by 0.5% in the first quarter. FMR LLC now owns 18,178,211 shares of the company’s stock valued at $88,527,000 after acquiring an additional 89,870 shares during the last quarter. 80.81% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Further Reading: Cost of Goods Sold (COGS)

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.